Dabigatran Sandoz Capsules 75 mg

EUEMA:by INNUSDailyMed:Dabigatran AU:C B01AE07(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only 211914-51-1as etexilate:211915-06-9 216210as etexilate:135565674 6380as etexilate:6379 DB14726as etexilate:DB06695 187412as etexilate:4948999 as etexilate:2E18WX195X D09707as etexilate:D07144 CHEBI:70752as etexilate:CHEBI:70746 ChEMBL48361as etexilate:ChEMBL539697 4CC (PDBe,RCSB PDB) DTXSID50175419 Interactive imageas etexilate:Interactive image CN1C=2C(=CC(C(N(CCC(O)=O)C3=CC=CC=N3)=O)=CC2)N=C1CNC4=CC=C(C(=N)N)C=C4as etexilate: CN1C=2C(=CC(C(N(CCC(OCC)=O)C3=CC=CC=N3)=O)=CC2)N=C1CNC4=CC=C(C(NC(OCCCCCC)=O)=N)C=C4 InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)K​‍​​​​​‍​‍‍‍‍​‍‍ey:YBSJFWOBGCMAKL-UHFFFAOYSA-Nas etexilate: InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)Key:KSGXQBZTULBEEQ-UHFFFAOYSA-N Dabigatran, sold under the brand namePradaxaamong others, is ananticoagulantused to treat and preventblood clotsand to preventstrokein people withatrial fibrillation.It is commonly used to prevent blood clots followinghiporknee replacementand in those with a history of prior clots.and is used as an alternative towarfarin; it does not require monitoring by blood tests.In a meta-analysis of seven different studies, there was no benefit of dabigatran over warfarin in preventingischemic stroke; however, dabigatran was associated with a lower hazard for intracranial bleeding compared with warfarin, but also had a higher risk of gastrointestinal bleeding.It is taken by mouth. Common side effects include bleeding andgastritis.Other side effects may includebleeding around the spineand allergic reactions such asanaphylaxis.In cases of severe bleeding, it can be reversed with the antidote,idarucizumab.Use is not recommended during pregnancy orbreastfeeding.Compared to warfarin it has fewerinteractions with other medications.It is adirect thrombin inhibitor. Dabigatran was approved for medical use in the US in 2010.It is on theWorld Health Organization's List of Essential Medicines.In 2020, it was the 306th most commonly prescribed medication in the United States, with more than 1million prescriptions.Dabigatran is available ageneric medication.